ON-DEMAND webinar: Intrinsic and acquired resistance to EGFR TKIs: new therapies on the horizon


Learning objectives:         

After attending this symposium, participants should be able to:

  • Highlight the importance of intrinsic and acquired EGFR resistance mutations in NSCLC and how this can impact patient outcomes
  • Understand the increasing role of genetic and molecular profiling and biomarkers in tailoring therapy
  • Describe how current and future research in the treatment of NSCLC may drive therapeutic decisions for patients with specific activating and resistance EGFR mutations


Steering Committee:

  • Pilar Garrido (Spain)
  • Marina Garassino (Italy) 



  • Benjamin Besse (France)
  • Lecia Sequist (USA) 
  • Matthew Krebs (UK)
  • Zosia Piotrowska (USA)


This educational activity has been awarded 2 CPD points by CPDUK, a globally recognised provider of CPD.

More Info
123 Minutes
EM-39341 - Date of preparation: August 2020